1. Long-term follow-up of high-dose chemotherapy with autologous stem-cell transplantation and response-adapted whole-brain radiotherapy for newly diagnosed primary CNS lymphoma: results of the multicenter Ostdeutsche Studiengruppe Hamatologie und Onkologie OSHO-53 phase II study.
- Author
-
Kiefer T, Hirt C, Späth C, Schüler F, Al-Ali HK, Wolf HH, Herbst R, Maschmeyer G, Helke K, Kessler C, Niederwieser D, Busemann C, Schroeder H, Vogelgesang S, Kirsch M, Montemurro M, Krüger WH, and Dölken G
- Subjects
- Adolescent, Adult, Aged, Central Nervous System Neoplasms mortality, Combined Modality Therapy, Cranial Irradiation, Female, Follow-Up Studies, Humans, Karnofsky Performance Status, Lymphoma mortality, Male, Middle Aged, Quality of Life, Transplantation, Autologous, Antimetabolites, Antineoplastic administration & dosage, Central Nervous System Neoplasms therapy, Lymphoma therapy, Methotrexate administration & dosage, Stem Cell Transplantation
- Abstract
Background: We previously reported the results of a phase II study for patients with newly diagnosed primary central nervous system lymphoma treated with autologous peripheral blood stem-cell transplantation (aPBSCT) and response-adapted whole-brain radiotherapy (WBRT). Now, we update the initial results., Patients and Methods: From 1999 to 2004, 23 patients received high-dose methotrexate. In case of at least partial remission, high-dose busulfan/thiotepa (HD-BuTT) followed by aPBSCT was carried out. Patients refractory to induction or without complete remission after HD-BuTT received WBRT. Eight patients still alive in 2011 were contacted and Mini-Mental State Examination (MMSE) and the European Organisation for Research and Treatment of Cancer quality-of-life questionnaire (QLQ)-C30 were carried out., Results: Of eight patients still alive, median follow-up is 116.9 months. Only one of nine irradiated patients is still alive with a severe neurologic deficit. In seven of eight patients treated with HD-BuTT, health condition and quality of life are excellent. MMSE and QLQ-C30 showed remarkably good results in patients who did not receive WBRT. All of them have a Karnofsky score of 90%-100%., Conclusions: Follow-up shows an overall survival of 35%. In six of seven patients where WBRT could be avoided, no long-term neurotoxicity has been observed and all patients have an excellent quality of life.
- Published
- 2012
- Full Text
- View/download PDF